Home blood pressure monitoring with a target of 120-130 mmHg and beta-blockers as first-line therapy are recommended for managing hypertension in haemodialysis patients.
May inform BP variability monitoring in HD hypertension; leaves open causal role of volume overload pending prospective validation.
Hypertension is frequently diagnosed among patients with chronic kidney disease (CKD) and often remains poorly controlled in end stage kidney disease (ESKD) especially in haemodialysis patients. These patients are characterized by higher blood pressure variability than the general population. Volume overload is a primary factor contributing into the pathogenesis of hypertension in this cohort. In the diagnosis and monitoring of hypertension in haemodialysis patients with chronic kidney disease self-measured of blood pressure at home done during the days between haemodialysis sessions should be considered. Home blood pressure measurements are of greater prognostic value than haemodialysis unit recording. Target-values of blood pressure in haemodialysis patients are still matter of debate. However, self-measured systolic blood pressure values at home between 120 to 130 mmHg are associated with the best prognosis in haemodialysis patients with CKD. Among not pharmacological methods of antihypertensive treatment in haemodialysis patients with CKD reducing volaemia by increasing ultrafiltration during haemodialysis procedures, individualization of sodium concentration in the dialysis fluid and low sodium diet should be listed. While, in the pharmacotherapy b-adrenergic antagonists seem to be the drugs of first choice.
No takes yet. Share an insight, caveat, or question.
Pokora et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: